ARCHIVES

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Goodfellow To Lead Gynecologic Oncology Research Team At Ohio State University

January 11, 2013

Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy

September 27, 2013

HHS Task Force Says NCI Drug Program Effective, Otters Suggestions; DeVita Responds

March 26, 1982

Guest Editorial: FDA Must Address Economic Incentives to Resolve Drug Shortages Permanently

February 24, 2012

DCE Board Ok’s New RFA Programs worth $14 Million

June 29, 1990

Bennett Of NYU Heads NCI Director Search Committee

March 11, 1977